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Abstract
Buprenorphine is mainly metabolized by the cytochrome P450 (CYP) 3A4 enzyme.
The aim of this study was to evaluate the role of first-pass metabolism in the inter-
action of rifampicin and analgesic doses of buprenorphine. A four-session paired
cross-over study design was used. Twelve subjects ingested either 600 mg oral
rifampicin or placebo once daily in a randomized order for 7 days. In the first part
of the study, subjects were given 0.6-mg (placebo phase) or 0.8-mg (rifampicin
phase) buprenorphine sublingually on day 7. In the second part of the study, sub-
jects received 0.4-mg buprenorphine intravenously. Plasma concentrations of
buprenorphine and urine concentrations of buprenorphine and its primary
metabolite norbuprenorphine were measured over 18 h. Adverse effects were
recorded. Rifampicin decreased the mean area under the dose-corrected plasma
concentration–time curve (AUC0–18) of sublingual buprenorphine by 25% (geo-
metric mean ratio (GMR): 0.75; 90% confidence interval (CI) of GMR: 0.60, 0.93)
and tended to decrease the bioavailability of sublingual buprenorphine, from 22%
to 16% (P = 0.31). Plasma concentrations of intravenously administered buprenor-
phine were not influenced by rifampicin. The amount of norbuprenorphine
excreted in the urine was decreased by 65% (P < 0.001) and 52% (P < 0.001) after
sublingual and intravenous administration, respectively, by rifampicin. Adverse
effects were frequent. Rifampicin decreases the exposure to sublingual but not
intravenous buprenorphine. This can be mainly explained by an enhancement of
CYP3A-mediated first-pass metabolism, which sublingual buprenorphine only par-
tially bypasses. Concomitant use of rifampicin and low-dose sublingual buprenor-
phine may compromise the analgesic effect of buprenorphine.
Abbreviations
Ae, The cumulative amount of free unconjugated buprenorphine and norbuprenor-
phine excreted into urine; AUC, The area under the plasma concentration–time
curve; CI, confidence interval; Cmax, The peak plasma concentrations; F%, relative
bioavailability; GMR, Geometric mean ratios; MRM+, positive multireaction moni-
toring detection mode; SD, standard deviation; Tmax, Time to the peak plasma con-
centration; UGT, UDP-glucuronosyl transferases.
Introduction
Buprenorphine is a widely used partial l-opioid receptor
agonist. In low doses, it is used as an analgesic and, in
moderate or high doses, it is used in the treatment of
opioid withdrawal symptoms and maintenance therapy of
opioid-dependent patients. In recent years, transdermal
formulations have increased its use in the treatment of
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moderate chronic pain (Fredheim et al. 2010; Zin et al.
2014). In the United Kingdom, use of buprenorphine for
chronic noncancer pain in primary care has increased by
16.5-fold during the past decade (Zin et al. 2014).
Buprenorphine is extensively metabolized. Due to first-
pass metabolism, the bioavailability of oral buprenorphine
is very low (about 10–16%) and that of sublingual
buprenorphine somewhat higher (30–55%), but data from
different studies is very variable (Bullingham et al. 1982;
Kuhlman et al. 1996; Mendelson et al. 1997; Nath et al.
1999; Cowan et al. 2005). After sublingual administration
of buprenorphine, peak plasma concentrations are
reached in 1–3 h (Bullingham et al. 1981; McAleer et al.
2003; Ciraulo et al. 2006).
The main metabolic pathway of buprenorphine is N-
dealkylation to an active metabolite norbuprenorphine,
catalyzed mainly (65%) by cytochrome P450 (CYP) 3A4,
but also by CYP3A5 and CYP2C8 (Iribarne et al. 1997;
Kobayashi et al. 1998; Moody et al. 2002; Picard et al.
2005; Chang et al. 2006). Buprenorphine and norp-
buprenorphine are further conjugated to buprenorphine-
3-glucuronide and norbuprenorphine-3-glucuronide by
UDP-glucuronosyl transferases (UGT) (Chang and
Moody 2009), at least the first of which is pharmacologi-
cally active (Brown et al. 2011). Other metabolic path-
ways yield hydroxylated (M1–M5) and possibly other
oxidative metabolites (Picard et al. 2005; Chang et al.
2006). Buprenorphine is mainly excreted as metabolites in
bile (80–90%) and urine (10–30%) (Brewster et al. 1981;
Cone et al. 1984).
Drug–drug interaction studies in opioid-dependent
users of high-dose sublingual buprenorphine show that
many CYP3A4 inhibitors such as atazanavir, ritonavir,
and boceprevir increase plasma concentrations of
buprenorphine (McCance-Katz et al. 2006, 2007; Hul-
skotte et al. 2015). Ketoconazole, however, has no effect
on plasma concentrations of buprenorphine during trans-
dermal administration in healthy subjects (Kapil et al.
2012). Although rifampicin has decreased greatly plasma
buprenorphine concentrations causing opioid withdrawal
symptoms in opioid-dependent persons on stable
high-dose sublingual buprenorphine/naloxone treatment
(McCance-Katz et al. 2011), its effect on low-dose
buprenorphine has not previously been reported. Further-
more, most of the opioid-dependent patients in the
above-mentioned study (McCance-Katz et al. 2011) were
hepatitis C-positive and smokers, and many of them had
used also other substances. In addition, effects of rifampi-
cin on steady-state pharmacokinetics of buprenorphine
are not necessarily identical with its effects on single-dose
pharmacokinetics.
After sublingual administration, a part of buprenor-
phine dose bypasses the first-pass metabolism as it is
absorbed through the oral mucosa, and a part is swal-
lowed and undergoes first-pass metabolism in the intesti-
nal wall and liver. Enhancement of CYP3A4 activity by
rifampicin (Niemi et al. 2003) may thus compromise the
analgesic effects of buprenorphine. To our knowledge,
neither the effect of rifampicin on intravenous adminis-
tration of buprenorphine nor the role of first-pass meta-
bolism in the magnitude of the rifampicin–buprenorphine
interaction is known. Thus, we conducted a study to eval-
uate the effect of rifampicin on the pharmacokinetics of
sublingual and intravenous buprenorphine in healthy sub-
jects, using low doses applicable in the treatment of pain.
Materials and Methods
The study protocol was approved by the Ethics Commit-
tee of the Hospital District of Southwest Finland and by
the Finnish National Agency for Medicines. It was regis-
tered in the EudraCT clinical trials register under code
number 2012-002871-32. Good Clinical Practice and and
International Council for Harmonisation regulations were
followed in this study.
Subjects
Written informed consent was obtained from 12 healthy
subjects, 5 women and 7 men (age range from 19 to
23 years and weight range from 57 to 95 kg). Their gen-
eral health was good as assessed by their medical history,
clinical examination, routine laboratory tests, and an
ECG. Pregnancy tests for women and urine drug screen-
ing tests were negative. The subjects were not on any reg-
ular medication, including hormonal contraceptives.
Female participants were instructed to use nonhormonal
contraception throughout the study. Smoking was not
allowed during the study. Participants abstained from any
products with known effects on CYP enzyme activity such
as herbal and grapefruit products for 4 weeks prior to the
study. The risk of participants to develop opioid abuse
was estimated low as evaluated by the Finnish translation
of the Abuse Questions (Michna et al. 2004).
Study outline and drug administration
A four-session paired cross-over study design was used at
intervals of 4 weeks. During each session, the subjects
ingested as pretreatments either 600 mg oral rifampicin
(Rimapen 600 mg tabl, Orion, Finland) or placebo once
daily at 8 P.M. for 7 days in randomized order. Adherence
to the dosing schedule was assessed by use of mobile
telephone text messages. In the first part of the study,
subjects were given sublingually 0.6-mg or 0.8-mg
buprenorphine (Temgesic 0.2 mg resoriblets; RB
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Pharmaceuticals Limited, Slough, Great Britain) after pla-
cebo or rifampicin, respectively, on day 7 at 11 A.M. after
fasting overnight. In the second part of the study, subjects
received an intravenous bolus of 0.4-mg buprenorphine
(Temgesic 0.3 mg/mL inj; RB Pharmaceuticals Limited,
Slough, Great Britain) after rifampicin or placebo. Sub-
jects were served standardized meals 4 and 8 h after
buprenorphine. For nausea or vomiting, intravenous tro-
pisetron was used, if clinically indicated. For itch or urti-
caria, cetirizine hydrochloride was used if indicated.
Subjects consented to abstain from any products with
known effects on CYP enzyme activity as well as alcohol,
tea, coffee, cola, and energy drinks during the test days.
Blood samples (10 mL) were collected into ethylenedi-
aminetetraacetic acid-containing tubes for pharmacoki-
netic measurements immediately before and 30 min, 1,
1.5, 2, 3, 4, 5, 6, 8, 10, 12, and 18 h after the administra-
tion of buprenorphine. Plasma was separated within
30 min and stored at 70°C until analysis. Urine was col-
lected up to 18 h after buprenorphine administration.
Urine aliquota were stored at 70°C until analysis. In the
second part of the study, another venous cannula was
inserted on the opposite forearm for intravenous adminis-
tration of buprenorphine.
Adverse effects
Adverse effects were recorded before and 3 and 6 h after
buprenorphine administration by a questionnaire.
Determination of buprenorphine and
norbuprenorphine concentrations
Mass spectrometric detection of buprenorphine and nor-
buprenorphine was carried out using API 3000 Triple
Quadrupole tandem mass spectrometer (Applied Biosys-
tems MDS Sciex, Toronto, ON, Canada) as previously
described (Ceccato et al. 2003), with minor modifications.
The internal standards (buprenorphine-D4 and nor-
buprenorphine-D3) were added to samples, quality control
samples, and reference standards before other preanalytical
procedures. Plasma and urine samples (0.5 ml) were pre-
pared by use of a Bond Elut C8 solid phase extraction
(Agilent Technologies, Lake Forest, CA). Gradient
chromatography was carried out using a Model 1100 Series
liquid chromatograph (Agilent Technologies) equipped
with a binary pump, a vacuum degasser, a thermostated
column compartment, and an autosampler. Atlantis HILIC
Silica analytical column (2.1 9 100 mm; Waters, Milford,
MA) with precolumn (2.1 mm 9 10 mm; Waters) were
used at 30°C. The mobile phase A consisted of a mixture of
acetonitrile: methanol: 10 mmol/L ammonium formate +
0.2% formic acid (90:5:5, v/v/v), and the mobile phase B of
10 mmol/L ammonium formate + 0.2% formic acid. The
gradients were as follows: 0–0.5 min B = 0%, 0.5–5 min
B?40%, 5–8 min B = 40%, 8.0–8.1 min B?0%, and 8.1–
20 min B = 0%. The flow rate was 0.2 mL/min. The mass
spectrometer was operated in positive multireaction moni-
toring (MRM+) detection mode with electro spray ioniza-
tion. The selected ion transitions used for quantification
were as follows: m/z 468.3 to m/z 55.1 for buprenorphine,
m/z 414.3 to m/z 340.2 for norbuprenorphine, and m/z
472.3 to m/z 59.2 and m/z 417.3 to m/z 83.2 for the internal
standards, respectively. The low limit of quantification
(LLQ) for plasma buprenorphine was 0.02 ng/mL, and for
norbuprenorphine 0.10 ng/mL. For urine buprenorphine
and norbuprenorphine, the LLQ was 0.5 ng/mL. The inter-
day coefficients of variation (CV%) were for plasma
buprenorphine 8.0% at 5.3 ng/mL, 8.7% at 0.5 ng/mL, and
6.1% at 0.05 ng/mL, and for norbuprenorphine 3.7% at
4.8 ng/mL and 8.7% at 0.48 ng/mL.
Pharmacokinetic measurements
The peak plasma concentrations (Cmax) and correspond-
ing Cmax times (tmax) of buprenorphine were observed
directly from the data. After sublingual administration of
buprenorphine, its plasma concentrations were not quan-
tifiable at 18 h in eight subjects, from 8 h on in two sub-
jects, and from 6 h on in one subject. Norbuprenorphine
concentrations were below the quantitation limit in most
of the plasma samples; therefore, its pharmacokinetics in
plasma were not calculated. The area under the plasma
concentration–time curve (AUC) values from 0 to 18 h
(AUC0–18) was calculated for buprenorphine by noncom-
partmental methods using the WinNonlin pharmacoki-
netics program (version 4.1; Pharsight, Mountain View,
CA). We also calculated the relative bioavailability (F %)
of buprenorphine, and the cumulative amount of free
unconjugated buprenorphine and norbuprenorphine
excreted into urine from 0 to 18 h (Ae). Pharmacokinetic
parameters were normalized for a buprenorphine dose of
1.0 mg.
Statistical analysis
In view of our previous drug–drug interaction studies
(Nieminen et al. 2009), we calculated that 10 subjects
would be needed to detect a 30% difference in the area
under the concentration–time curve (AUC0–18) of
buprenorphine at a power of 80% and a level of signifi-
cance of P < 0.05. To be prepared for dropouts, we
recruited 12 subjects.
The data were evaluated for normality of distribution
using probit plots and the Shapiro–Wilk’s W-test. Data
were log transformed for analysis, but were reported as
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nontransformed results. The AUC0–18 of buprenorphine
was the primary outcome variable in the study. Geometric
mean ratios (GMR) with 90% confidence intervals (CIs)
were calculated for the pharmacokinetic variables. Lack of
interaction was assumed if the 90% CI of the GMRs for
pharmacokinetic variables were within the acceptance
limit of 0.8–1.25. Differences in pharmacokinetic variables
between rifampicin and placebo phases were analyzed
using paired Student’s t-test except for tmax which was
analyzed using the Wilcoxon signed-ranks test. Differ-
ences were regarded as statistically significant at P < 0.05.
The results are expressed as mean values  standard devi-
ation (SD). All data were analyzed using R language for
Statistical Computing, version 3.1.3 (R Core Team 2015),
in RStudio, version 0.99.878 (RStudio 2015).
Results
Mean plasma concentrations of sublingual and intra-
venous buprenorphine during rifampicin and placebo
phases are shown in Figure 1. Interindividual differences
in pharmacokinetic variables were considerable (Table 1,
Figs 2 and 3).
Rifampicin decreased the mean AUC0–18 of sublingual
buprenorphine by 25% (GMR: 0.75; 90% CI of GMR:
0.60, 0.93) (Table 1, Figs. 1, 2). The bioavailability of
sublingual buprenorphine decreased from the control
value of 22 to 16% by rifampicin, but the change was not
statistically significant (GMR: 0.84; 90% CI of GMR: 0.62,
1.13) (Table 1, Fig. 2). After intravenous buprenorphine
administration, there were no statistically significant dif-
ferences in plasma buprenorphine concentrations between
the placebo and rifampicin phases. Rifampicin decreased
the cumulative excretion of free, nonconjugated nor-
buprenorphine in urine by 65% after sublingual (GMR:
0.35; 90% CI of GMR: 0.24, 0.51) and by 52% after intra-
venous (GMR: 0.48; 90% CI of GMR: 0.39, 0,58) admin-
istration, but the effect on buprenorphine excretion was
less consistent (Table 1, Fig. 3).
All subjects experienced mild-to-moderate adverse
effects during the study and needed medication (tropise-
tron) for nausea after buprenorphine. Nausea was more
pronounced during the intravenous than sublingual part
of the study. Eight subjects needed medication (cetirizine
hydrochloride) for itch or urticaria during the intra-
venous part of the study.
Discussion
The results of this study show that rifampicin reduces the
exposure to sublingual, but not to intravenous buprenor-
phine. Although this finding is most likely caused by an
induction of CYP3A4 activity by rifampicin in the intesti-
nal wall and liver, other mechanisms such as enhance-
ment of UGT or P-glycoprotein activities may also be
involved. The sublingual route of administration of
buprenorphine is more vulnerable to the effects of an
interaction with rifampicin than the intravenous one, as
sublingual buprenorphine only partially avoids the induc-
tion of CYP3A4-mediated gastrointestinal metabolism by
rifampicin.
CYP3A4 is involved in several steps in the metabolic
pathways of buprenorphine. It catalyzes not only N-deal-
kylation of buprenorphine to norbuprenorphine but also
Figure 1. Mean plasma (SD) concentrations of buprenorphine in 12 healthy subjects after 0.6-mg (placebo phase) or 0.8-mg (rifampicin phase)
sublingual buprenorphine or 0.4-mg intravenous buprenorphine on the seventh day of pretreatment with placebo (open circles) or rifampicin
(filled circles) 600 mg once daily for 7 days. Values are normalized for a buprenorphine dose of 1.0 mg. Buprenorphine concentrations are shown
both on an arithmetic and a semilogarithmic scale (inset).
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hydroxylation of buprenorphine to M1, and conversion
of norbuprenorhine into M3 (Chang et al. 2006; Moody
et al. 2009). In this study, rifampicin decreased the mean
AUC0–18 of sublingual buprenorphine by 25% in healthy
subjects. A previous study shows that when opioid-depen-
dent subjects on stable, high doses of sublingual
buprenorphine/naloxone were treated with rifampicin
600 mg daily for 15 days, a 70% decrease in the mean
AUC of buprenorphine was detected, and withdrawal
symptoms were frequent (McCance-Katz et al. 2011). It is
possible that the smaller effect of rifampicin on the expo-
sure to sublingual buprenorphine in this study was due to
shorter duration of rifampicin administration, that is, that
the induction was not yet at its maximum within 7 days
(Niemi et al. 2003). However, also different study popula-
tions, and a single, small buprenorphine dose versus over
10 times higher daily doses, administered up to steady
state (McCance-Katz et al. 2011) may explain quantita-
tively different effects of rifampicin. Induction of CYP3A4
by rifampicin reduces the exposure also to several other
Table 1. Dose-normalized pharmacokinetic parameters of buprenorphine and norbuprenorphine after sublingual administration of 0.6 mg
(placebo phase) or 0.8 mg (rifampicin phase), or intravenous administration of 0.4 mg buprenorphine on the seventh day of pretreatment with
rifampicin (600 mg once daily for 7 days) or placebo in 12 healthy subjects.
Parameter Placebo Rifampicin P-value
Geometric mean ratio
(90% CI)
Sublingual phase
Buprenorphine
Cmax (ng/mL) 0.36  0.15 0.30  0.17 0.041 0.78 (0.64, 0.94)
tmax (h) 1.5 (1–3) 2 (1–3) —
AUC0-18 (ng h/mL) 1.64  0.74 1.36  0.87 0.035 0.75 (0.60, 0.93)
F (%) 22  10 16  11 0.31 0.84 (0.62, 1.13)
Ae (lg) 0.21  0.20 0.17  0.20 0.82 0.71 (0.04, 12.52)
Norbuprenorphine
Ae (lg) 4.35  1.85 1.47  0.66 <0.001 0.35 (0.24, 0.51)
Intravenous phase
Buprenorphine
AUC0–18 (ng h/mL) 5.32  3.18 4.53  1.64 0.37 0.92 (0.77, 1.08)
Ae (lg) 1.5  0.7 2.7  2.3 0.67 1.18 (0.59, 2.39)
Norbuprenorphine
Ae (lg) 4.6  1.9 2.3  1.1 <0.001 0.48 (0.39, 0.58)
Values are normalized for a buprenorphine dose of 1.0 mg. Data are shown as mean  standard deviation (SD) and as the geometric mean ratios
with the 90% confidence interval (CI) in parenthesis – except for tmax, which is given as median and range.
CI, confidence interval; Cmax, peak plasma concentration; tmax, concentration peak time; AUC0–18, area under curve from 0 to 18 h; Ae, amount
excreted into urine within 18 h, F % relative bioavailability.
Figure 2. Box-plot analysis and individual parameters for maximum concentration (Cmax), area under plasma concentration–time curve values
from 0 to 18 h (AUC0–18), and relative bioavailability (F %) in 12 healthy subjects after 0.6 mg (placebo phase) or 0.8 mg (rifampicin phase)
sublingual buprenorphine on the seventh day of pretreatment with placebo or rifampicin 600 mg once daily for 7 days. The horizontal line in the
box represents the median, white diamonds show the mean, the box shows the interquartile range, and whiskers show the 10th and 90th
percentiles. Range of fold increase for AUC0–18 was 0.3–10 ng h/mL during the sublingual part and 0.62–1.50 ng h/mL during the intravenous
part of the study. Values are normalized for a buprenorphine dose of 1.0 mg.
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opioid substrates of CYP3A4, such as methadone, alfen-
tanil, oxycodone, and tramadol (Kharasch et al. 1997,
2004; Nieminen et al. 2009; Saarikoski et al. 2013).
Although rifampicin can also act as a competitive inhibi-
tor of organic anion transporting polypeptide (OATP)
1B1 and possibly of CYP2C8/CYP3A4 (Bidstrup et al.
2004; Kajosaari et al. 2005), this effect was avoided in this
study by administering buprenorphine 15 h after the last
dose of rifampicin.
Rifampicin enhances the activities of UGTs and P-gly-
coprotein (Greiner et al. 1999; Niemi et al. 2003; Soars
et al. 2004). As buprenorphine and norbuprenorphine are
conjugated to buprenorphine-3-glucuronide and nor-
buprenorphnine-3-glucuronide by UGTs (Chang and
Moody 2009), it is possible that enhanced activity of
UGTs by rifampicin contributed to the pharmacokinetic
changes seen in this study. The role of P-glycoprotein in
the transport of buprenorphine is less clear. In vitro stud-
ies in rodents suggest that norbuprenorphine, but not
buprenorphine, is a substrate for P-glycoprotein, but its
role in the transport of buprenorphine in humans is yet
to be solved (Hassan et al. 2009; Brown et al. 2012).
Figure 3. The individual amounts of urinary buprenorphine and norbuprenorphine excreted during 18 h in 12 healthy subjects after 0.6 mg
(placebo phase) or 0.8 mg (rifampicin phase) sublingual buprenorphine or 0.4 mg intravenous buprenorphine on the seventh day of pretreatment
with placebo or rifampicin 600 mg once daily for 7 days. The horizontal line in the box represents the median, white diamonds show the mean,
the box shows the interquartile range, and whiskers show the 10th and 90th percentiles. Values are normalized for a buprenorphine dose of
1.0 mg.
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CYP2C8 is involved in the formations of norbuprenor-
phine and M1 from buprenorphine (Moody et al. 2002;
Chang et al. 2006). As rifampicin is an inducer and inhi-
bitor of CYP2C8 (Kajosaari et al. 2005), it is possible that
this enzyme may have contributed to the findings of this
study. However, its role in the metabolism of buprenor-
phine is probably less important than that of CYP3A4, as
in vitro studies suggest that the potency of rifampicin to
induce CYP3A4 exceeds that of CYP2C8 (Dixit et al.
2007).
Bioavailability of oral buprenorphine is only approxi-
mately 10-16% due to its extensive first-pass metabolism
in the intestinal wall and liver (Cowan et al. 2005).
Sublingual administration of buprenorphine increases
bioavailability to about 30–55% (Bullingham et al. 1982;
Kuhlman et al. 1996; Mendelson et al. 1997; Nath et al.
1999; Cowan et al. 2005) as buprenorphine is markedly
absorbed transmucosally from the oral cavity (Weinberg
et al. 1988). Even though the participants in this study
were well informed about how to use the sublingual
tablet, they most likely ingested a part of the dose with
saliva predisposing sublingual buprenorphine to enhanced
intenstinal and hepatic first-pass metabolism by rifampi-
cin. This was reflected by a decrease in bioavailability of
buprenorphine from 22% to 16% after pretreatment with
rifampicin.
Only 10‒30% of a buprenorphine dose is excreted in
urine, mainly as metabolites (Cone et al. 1984). As nor-
buprenorphine is less lipophilic than the parent drug, its
excretion into urine occurs, to some extent, also in the
unconjugated form. After the sublingual administration of
buprenorphine, the excretion of unconjugated nor-
buprenorphine was about 10-fold greater than that of
buprenorphine, whereas after the intravenous administra-
tion, this difference did not exist. Rifampicin decreased
the amount of unconjugated norbuprenorphine in urine
after both sublingual and intravenous buprenorphine dos-
ing, which may reflect a shift in the metabolic pathway
toward hydroxylation of buprenorphine or norbuprenor-
phine by CYP3A4, or possibly, induction of further meta-
bolism of norbuprenorphine by UGTs after rifampicin
pretreatment (Chang et al. 2006; Chang and Moody
2009). Similarly, pretreatment with the CYP3A4 inducer/
inhibitor efavirenz decreased urinary excretion of nor-
buprenorphine in subjects treated with buprenorphine/
naloxone combination for opioid dependency (Moody
et al. 2009).
The reduction in the AUC0–18 of buprenorphine by
rifampicin pretreatment was significant after sublingual,
but not after intravenous administration. This is a clini-
cally important finding, as sublingual buprenorphine is
more commonly used in the treatment of opioid depen-
dence, opioid withdrawal symptoms, and pain than the
intravenous formula. The interaction of low-dose sublin-
gual buprenorphine and rifampicin (or any other strong
CYP3A4 inducer) may predispose a patient to diminished
analgesic effects of buprenorphine or, on the other hand,
to enhanced side-effects if rifampicin treatment is
abruptly discontinued without a dose adjustment of
buprenorphine.
There were some strengths and limitations in our
study. The four-phase cross-over study design in healthy
volunteers under strictly controlled conditions was used
to confirm compliance with, for example, blood sampling
and urine collection. Buprenorphine was given without
naloxone to avoid any possible pharmacokinetic interfer-
ences of naloxone with buprenorphine and rifampicin.
For safety reasons, we used single small doses of
buprenorphine. Consistent with previous studies (Harris
et al. 2004; Escher et al. 2007), adverse effects such as
nausea and itch were frequent. Nausea and changes in sal-
iva excretion may explain a part of the interindividual
variability after sublingual administration. Nausea was
treated with tropisetron which, theoretically, might have
affected the results. However, as tropisetron is a very
weak inhibitor of CYP2D6, and its concentrations
achieved in vivo are at least one order of magnitude
lower than its Ki-value (16 microM) needed for inhibi-
tion of CYP2D6 (Firkusny et al. 1995; Ho and Gan
2006), its effect on our results was most likely minimal.
Itch and urticarial were treated with cetirizine. As ceti-
rizine has a negligible interaction with liver enzymes
(Chen 2008), this most likely did not influence the results
of this study. Theoretically, the use of different doses of
buprenorphine during various phases of the study might
have biased dose-corrected results if buprenorphine had
nonlinear pharmacokinetics. However, although the phar-
macokinetics of buprenorphine appears to be nonlinear
in rats (Gopal et al. 2002), there is no indication for non-
linear buprenorphine pharmacokinetics in humans
(McAleer et al. 2003). Thus, there is no evidence that the
dose of buprenorphine would affect the magnitude of its
interaction with rifampicin.
Low-dose buprenorphine is increasingly used in the
treatment of chronic pain but drug–drug interaction
studies have mainly been conducted in subjects using
intermediate or high doses for opioid dependency. In this
study, rifampicin decreased the exposure to a low dose of
sublingual buprenorphine, but did not affect intravenous
buprenorphine exposure indicating that the sublingual
route of administration is more vulnerable to the effects
of an interaction with CYP3A4 inducers than the intra-
venous one. This is most likely explained by the fact that
sublingual buprenorphine only partially avoids the
enhanced first-pass metabolism by rifampicin. In clinical
use, this interaction may be associated with diminished
ª 2016 The Authors. Pharmacology Research & Perspectives published by John Wiley & Sons Ltd,
British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics.
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analgesic effects of low-dose sublingual buprenorphine.
Buprenorphine interaction with rifampicin can be avoided
by choosing an intravenous route of administration when
appropriate.
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